Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 11, 2020- Focusing in Scientific Innovation and Collaboration in Oncology, Alzheimer's disease and other Neurological DisordersEisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo, Japan) announced today the relocation of its New Jersey-based...
Aug 11, 2020Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor...
Aug 7, 2020• Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 • If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s diseaseCAMBRIDGE, Mass. and TOKYO, August 7, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Jul 24, 2020- One oral presentation and eight posters, highlighting Eisai's investigational novel therapies being studied to treat Alzheimer's disease (AD) and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and information from the company's robust AD pipeline, including BAN2401 and...
-
Jul 13, 2020
The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United...
-
Jul 8, 2020If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease
CAMBRIDGE, Mass. and TOKYO, July 8, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics...
- Jul 8, 2020
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., July 8, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
-
Jun 1, 2020
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO® (lemborexant) CIV for the treatment of adults with insomnia, characterized by...
- May 29, 2020Results showed encouraging anticancer activity in both first-line and later lines, with an objective response rate (ORR) of 25.8% and 21%, respectively
Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...
- May 28, 2020Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...